Press Release

State and local dignitaries attend ribbon-cutting ceremonies in Bedford, Massachusetts

BILLERICA, Mass.--(BUSINESS WIRE)--Oct. 19, 2009-- Millipore Corporation (NYSE:MIL), a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today announced the completion of a $2 million solar panel installation project at its Bedford, Massachusetts, facility. Millipore Chairman and CEO Martin Madaus was joined by Massachusetts Governor Deval Patrick and other dignitaries at a ribbon-cutting ceremony to unveil the system, which will provide renewable energy for Millipore’s Bedford and Billerica, Mass. facilities.

“Millipore’s investment in solar energy reflects our commitment to reducing our environmental impact and developing the industry’s leading sustainability program,” said Madaus. “Our solar panel project would not have been possible without the support of the Governor and the State of Massachusetts. We look forward to a continued partnership with the State and hope other companies will implement sustainability initiatives to reduce their environmental impact, lower their costs, and make themselves more desirable business partners.”

Millipore’s solar panel project is one of the largest solar photovoltaic projects ever completed in Massachusetts and is the first renewable energy project the company has implemented in the U.S.

“Millipore is not only a leading employer in Massachusetts, but also a leader in creating our clean energy future,” said Governor Patrick. “Millipore is setting an impressive standard for energy efficiency and renewable energy, and showing other companies how to save energy and reduce their emissions through the Governor’s Clean Energy Challenge. Martin Madaus, who serves as co-chair of the state’s Climate Protection and Green Economy Advisory Committee, deserves to be commended for his leadership on climate change.”

Over the past six months, Millipore worked with several vendors to design and install the solar panel system, which includes 1383 Sharp panels and 4 Solectria inverters. It will produce about 352,000 KWH/yr or, approximately 35 homes worth of electricity, which will be used to augment the electricity purchased from the grid to run Millipore’s facilities.

“The primary focus of our sustainability program has been on reducing our environmental impacts—particularly waste, water and climate change,” said David Newman, Director of Sustainability for Millipore. “The changes we are implementing not only make sense for the environment, but they also have a considerable positive impact on our business. We are excited about completing the solar panel project, which marks an important continuation of our efforts to embrace renewable energy throughout the company.”

MILLIPORE’S SUSTAINABILITY INITIATIVE:

Launched in 2008, Millipore’s sustainability initiative is sponsored by the company’s CEO, Martin Madaus, PhD. It is focused on reducing the Company’s impact on climate change, reducing waste, and changing employee behaviors. Millipore has set a goal of reducing its greenhouse gas emissions by 20 percent between 2006 and 2011, and has already cut its emissions by 14 percent just two years into the program.

The company’s energy programs involve a multi-pronged approach, including intensive energy auditing, upgrades to boilers, compressors and lighting. In addition, demand response programs and installations of alternative energy complement our existing efficiency projects. At the Bedford campus alone, the company has cut its electricity consumption by 12 percent in the last year through energy efficiency measures alone. This is equivalent to 200 homes’ worth of energy.

About Millipore:

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER^TM

Research. Development. Production.

Safe Harbor Statement

Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug or vaccine; delay, suspension or termination of a customer’s volume production; fluctuations in the timing of customers’ orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Source: Millipore Corporation

Millipore Media Contact:
Millipore Corporation
Karen Marinella Hall
Director of Corporate Communications
Office: 978-715-1567
Cell: 508-212-9476
karen_hall@millipore.com
or
Investors:
Joshua Young
Director, Investor Relations
978-715-1527
joshua_young@millipore.com